Interview with Prof. Milena Ivanova MD, Molecular Biologist from the University Hospital Aleksandrovska

26/06/2020

The following interview is part of our interview series that we are conducting with Key Opinion Leaders, Experts and Business Managers within the HLA field. In this interview, Prof. Milena Ivanova MD, Molecular Biologist from the University Hospital Aleksandrovska talks about their experiences and thoughts on HLA laboratory activities. We...

How Immunotherapy of Cancer May Create Novel Clinical Utilities for HLA Typing

15/12/2017

Written by Dr. Attila Bérces (Founder and Chairman, Omixon) The article was originally published in ASHI Quarterly Q3 2017 While the role of HLA has been demonstrated in over hundred diseases, its clinical utility and impact outside transplantation has been limited. Transplantation still dominates the demand for HLA genotyping....

Human Leukocyte Antigen as a Critical Biomarker for the Adoption of Novel Immunotherapies of Cancer

15/06/2017

– Written by Attila Bérces (Founder and Chairman, Omixon) While the role of HLA has been demonstrated in over hundred diseases, its clinical utility and impact outside transplantation has been limited. Transplantation is still the dominant driver for the clinical HLA typing market. A new therapeutic paradigm in cancer immunotherapy...

2016 Omixon Spotlight – This is How We Rolled!

20/12/2016

“2016 will be even more challenging and eventful” – this is how we waved goodbye to 2015, hoping for an amazing and exciting sequel. And holy smoke, what a year we’ve had! We started 2016 with a bang – a national tender victory in France: Holotype HLA, our CE-IVD...

Cancer Immunotherapy Proved to be Fertile Ground for Personalized Medicine

14/09/2016

Written by Dr. Attila Berces, Chairman at Omixon. Share the original article on LinkedIn here… “We try to remember that medicine is for the patient. We try never to forget that medicine is for the people. It is not for the profits. The profits follow, and if we have remembered...